2843 related articles for article (PubMed ID: 22122739)
61. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
62. Urinary tract ultrasonography in the evaluation of haematuria--a report of over 1,000 cases.
Datta SN; Allen GM; Evans R; Vaughton KC; Lucas MG
Ann R Coll Surg Engl; 2002 May; 84(3):203-5. PubMed ID: 12092877
[TBL] [Abstract][Full Text] [Related]
63. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
[TBL] [Abstract][Full Text] [Related]
64. [Gross hematuria and usefulness of urinary cytology: Experience at hematuria one stop clinic.].
Sánchez Verdes P; Fernández-Pello S; González Rodríguez I; Salgado Plonski JJ; Alonso Calvar L; Suárez Sal PJ; Rodríguez Villamil L
Arch Esp Urol; 2021 Jun; 74(5):470-476. PubMed ID: 34080566
[TBL] [Abstract][Full Text] [Related]
65. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms.
Murphy WM; Rivera-Ramirez I; Medina CA; Wright NJ; Wajsman Z
J Urol; 1997 Dec; 158(6):2102-6. PubMed ID: 9366322
[TBL] [Abstract][Full Text] [Related]
66. The role of the bladder tumour antigen test in the management of gross haematuria.
Chong TW; Cheng C
Singapore Med J; 1999 Sep; 40(9):578-80. PubMed ID: 10628246
[TBL] [Abstract][Full Text] [Related]
67. Early results of bladder-cancer screening in a high-risk population of heavy smokers.
Steiner H; Bergmeister M; Verdorfer I; Granig T; Mikuz G; Bartsch G; Stoehr B; Brunner A
BJU Int; 2008 Aug; 102(3):291-6. PubMed ID: 18336612
[TBL] [Abstract][Full Text] [Related]
68. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
69. Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer.
Raitanen MP; Kaasinen E; Lukkarinen O; Kauppinen R; Viitanen J; Liukkonen T; Tammela TL;
Urology; 2001 Apr; 57(4):680-4. PubMed ID: 11306380
[TBL] [Abstract][Full Text] [Related]
70. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
Moonen PM; Kiemeney LA; Witjes JA
Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
[TBL] [Abstract][Full Text] [Related]
71. The role of urinary cytology for detection of bladder cancer.
Planz B; Jochims E; Deix T; Caspers HP; Jakse G; Boecking A
Eur J Surg Oncol; 2005 Apr; 31(3):304-8. PubMed ID: 15780568
[TBL] [Abstract][Full Text] [Related]
72. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
Raitanen MP;
World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
[TBL] [Abstract][Full Text] [Related]
73. Can reproductive characteristics predict bladder cancer in women with haematuria?
Yavuzcan A; Caglar M; Kayikci MA; Basaran E; Tekin A; Ozdemir E; Dilbaz S; Ustun Y; Cam HK
Asian Pac J Cancer Prev; 2013; 14(9):5107-10. PubMed ID: 24175784
[TBL] [Abstract][Full Text] [Related]
74. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
[TBL] [Abstract][Full Text] [Related]
75. 64-Slice CT urography: 30 months of clinical experience.
Martingano P; Stacul F; Cavallaro M; Casagrande F; Cernic S; Belgrano M; Cova M
Radiol Med; 2010 Sep; 115(6):920-35. PubMed ID: 20574699
[TBL] [Abstract][Full Text] [Related]
76. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.
D Elia C; Pycha A; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Vjaters E; Pycha A; Trenti E
J Clin Pathol; 2019 Feb; 72(2):140-144. PubMed ID: 30355587
[TBL] [Abstract][Full Text] [Related]
77. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
[TBL] [Abstract][Full Text] [Related]
78. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
[TBL] [Abstract][Full Text] [Related]
79. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria.
Sudakoff GS; Dunn DP; Guralnick ML; Hellman RS; Eastwood D; See WA
J Urol; 2008 Mar; 179(3):862-7; discussion 867. PubMed ID: 18221955
[TBL] [Abstract][Full Text] [Related]
80. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
